to sell Clade Therapeutics

LONDON: Syncona Ltd has signed an agreement for the sale of its portfolio company Clade Therapeutics to Century Therapeutics for $45 million. Century is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies. Syncona committed $30 million to…